Welcome to LookChem.com Sign In|Join Free

CAS

  • or

517920-59-1

Post Buying Request

517920-59-1 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • SAGECHEM/2-(3-Chlorobenzyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane/SAGECHEM/Manufacturer in China

    Cas No: 517920-59-1

  • No Data

  • No Data

  • No Data

  • SAGECHEM LIMITED
  • Contact Supplier

517920-59-1 Usage

Description

2-[(3-chlorophenyl)Methyl]-4,4,5,5-tetraMethyl-1,3,2-dioxaborolane is a boronic ester derivative, a chemical compound widely used in organic synthesis and pharmaceutical research. It features a boron atom bonded to oxygen and carbon atoms, with a 3-chlorophenylmethyl group and tetramethyl substitution on the boron atom. 2-[(3-chlorophenyl)Methyl]-4,4,5,5-tetraMethyl-1,3,2-dioxaborolane is recognized for its stability and its ability to participate in Suzuki-Miyaura coupling reactions, a method for creating carbon-carbon bonds in organic molecules, making it a valuable building block for complex organic molecules with specific pharmaceutical or biological activities.

Uses

Used in Organic Synthesis:
2-[(3-chlorophenyl)Methyl]-4,4,5,5-tetraMethyl-1,3,2-dioxaborolane is used as a reagent in organic synthesis for its ability to undergo Suzuki-Miyaura coupling reactions, which are crucial for creating carbon-carbon bonds in organic molecules. This property is essential for the development of complex organic structures.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 2-[(3-chlorophenyl)Methyl]-4,4,5,5-tetraMethyl-1,3,2-dioxaborolane is used as a building block for the creation of complex organic molecules with specific pharmaceutical or biological activities. Its unique structure and reactivity contribute to the design and synthesis of new drug candidates.
Used in Chemical Transformations:
2-[(3-chlorophenyl)Methyl]-4,4,5,5-tetraMethyl-1,3,2-dioxaborolane is utilized as a versatile reagent in various chemical transformations due to the stability of the dioxaborolane moiety. This makes it a useful tool in the synthesis of a wide range of organic compounds.

Check Digit Verification of cas no

The CAS Registry Mumber 517920-59-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,1,7,9,2 and 0 respectively; the second part has 2 digits, 5 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 517920-59:
(8*5)+(7*1)+(6*7)+(5*9)+(4*2)+(3*0)+(2*5)+(1*9)=161
161 % 10 = 1
So 517920-59-1 is a valid CAS Registry Number.

517920-59-1SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 15, 2017

Revision Date: Aug 15, 2017

1.Identification

1.1 GHS Product identifier

Product name 2-(3-Chlorobenzyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane

1.2 Other means of identification

Product number -
Other names 2-[(3-chlorophenyl)methyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:517920-59-1 SDS

517920-59-1Relevant articles and documents

Stereoselective gem-C,B-Glycosylation via 1,2-Boronate Migration

He, Zhi-Tao,Li, Rui-Peng,Liao, Qi-Ying,Ma, Chao,Wang, Miao,Zhao, Wei-Cheng

supporting information, p. 2460 - 2467 (2022/02/16)

A novel protocol is established for the long-standing challenge of stereoselective geminal bisglycosylations of saccharides. The merger of PPh3 as a traceless glycosidic leaving group and 1,2-boronate migration enables the simultaneous introduction of C-C and C-B bonds at the anomeric stereogenic center of furanoses and pyranoses. The power of this method is showcased by a set of site-selective modifications of glycosylation products for the construction of bioactive conjugates and skeletons. A scarce metal-free 1,1-difunctionalization process of alkenes is also concomitantly demonstrated.

(o-Phenylenediamino)borylstannanes: Efficient Reagents for Borylation of Various Alkyl Radical Precursors

Suzuki, Kensuke,Nishimoto, Yoshihiro,Yasuda, Makoto

supporting information, p. 3968 - 3973 (2020/12/30)

(o-Phenylenediamino)borylstannanes were newly synthesized to achieve radical boryl substitutions of a variety of alkyl radical precursors. Dehalogenative, deaminative, decharcogenative, and decarboxylative borylations proceeded in the presence of a radica

Structure-Based Optimization and Discovery of M3258, a Specific Inhibitor of the Immunoproteasome Subunit LMP7 (β5i)

Klein, Markus,Busch, Michael,Friese-Hamim, Manja,Crosignani, Stefano,Fuchss, Thomas,Musil, Djordje,Rohdich, Felix,Sanderson, Michael P.,Seenisamy, Jeyaprakashnarayanan,Walter-Bausch, Gina,Zanelli, Ugo,Hewitt, Philip,Esdar, Christina,Schadt, Oliver

, p. 10230 - 10245 (2021/07/26)

Proteasomes are broadly expressed key components of the ubiquitin-dependent protein degradation pathway containing catalytically active subunits (β1, β2, and β5). LMP7 (β5i) is a subunit of the immunoproteasome, an inducible isoform that is predominantly expressed in hematopoietic cells. Clinically effective pan-proteasome inhibitors for the treatment of multiple myeloma (MM) nonselectively target LMP7 and other subunits of the constitutive proteasome and immunoproteasome with comparable potency, which can limit the therapeutic applicability of these drugs. Here, we describe the discovery and structure-based hit optimization of novel amido boronic acids, which selectively inhibit LMP7 while sparing all other subunits. The exploitation of structural differences between the proteasome subunits culminated in the identification of the highly potent, exquisitely selective, and orally available LMP7 inhibitor 50 (M3258). Based on the strong antitumor activity observed with M3258 in MM models and a favorable preclinical data package, a phase I clinical trial was initiated in relapsed/refractory MM patients.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 517920-59-1